# Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome

Study · id `cardio:ct-nct06410352` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06410352](<https://clinicaltrials.gov/study/NCT06410352>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06410352

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 220 participants.

## Technical summary

Registry record NCT06410352. Non-randomized; no masking; primary purpose treatment. Start 2024-03-01 (actual); primary completion 2025-09-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 220 participants (planned count; ClinicalTrials.gov record NCT06410352, source copy `cardio:ctgov-nct06410352-2025-11-26`, retrieved 2026-10-26)
- Started: 2024-03-01 (actual) (ClinicalTrials.gov record NCT06410352, source copy `cardio:ctgov-nct06410352-2025-11-26`, retrieved 2026-10-26)
- Primary completion: 2025-09-30 (actual) (ClinicalTrials.gov record NCT06410352, source copy `cardio:ctgov-nct06410352-2025-11-26`, retrieved 2026-10-26)
- Completion: 2026-07-31 (anticipated) (ClinicalTrials.gov record NCT06410352, source copy `cardio:ctgov-nct06410352-2025-11-26`, retrieved 2026-10-26)
- Countries: Kazakhstan (ClinicalTrials.gov record NCT06410352, source copy `cardio:ctgov-nct06410352-2025-11-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06410352-2025-11-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome
- Condition: Metabolic Syndrome
- Intervention (Drug): Semaglutide, Empagliflozin
- Intervention (Procedure): Minigastric bypass
- Intervention (Dietary supplement): Analimentary detoxication
- Intervention (Behavioral): Ramadan fast's weight loss
- Lead sponsor: University Medical Center, Kazakhstan
- Lead sponsor class: OTHER
- Collaborator: Nazarbayev University School of Medicine
- Collaborator class: UNKNOWN
- Collaborator: Nazarbayev University
- Collaborator class: OTHER
- Collaborator: Astana Medical University
- Collaborator class: OTHER
- Collaborator: Public Association "Eurasian Society of Personalized Medicine"
- Collaborator class: UNKNOWN
- Collaborator: Ministry of Science and Higher Education of the Republic of Kazakhstan
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 63ce2f658eeb8b7f819030cea4416d73523b85a064c9643df60246c6db45aab5
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
